CY1109442T1 - Μεθοδος για την παρασκευη αλατων 5-[(r)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1h)-κινολιν-2-ονης, τα οποια ειναι χρησιμα ως αγωνιστες αδρενεργικων υποδοχεων - Google Patents

Μεθοδος για την παρασκευη αλατων 5-[(r)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1h)-κινολιν-2-ονης, τα οποια ειναι χρησιμα ως αγωνιστες αδρενεργικων υποδοχεων

Info

Publication number
CY1109442T1
CY1109442T1 CY20091100993T CY091100993T CY1109442T1 CY 1109442 T1 CY1109442 T1 CY 1109442T1 CY 20091100993 T CY20091100993 T CY 20091100993T CY 091100993 T CY091100993 T CY 091100993T CY 1109442 T1 CY1109442 T1 CY 1109442T1
Authority
CY
Cyprus
Prior art keywords
hydroxy
ylamino
indan
preparation
diahyl
Prior art date
Application number
CY20091100993T
Other languages
English (en)
Inventor
Olivier Lohse
Caspar Vogel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32927689&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1109442(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CY1109442T1 publication Critical patent/CY1109442T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44Palladium
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • C07D215/24Oxygen atoms attached in position 8
    • C07D215/26Alcohols; Ethers thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Materials Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Μέθοδος για την παρασκευή άλατος 5-[ (R)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1Η)-κινολιν-2-όνης. Η μέθοδος περιλαμβάνει τον σχηματισμό ενός όξινου άλατος της 5- [(R)-2 - (5 , 6 -διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυαιθυλο]-8-υποκατεστημένης οξυ-(1Η)-κινολιν-2-όνης (V), και την μετατροπή του όξινου άλατος σε ένα άλας 5 - [ (R)-2 - (5 , 6 -διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1Η)-κινολιν-2-όνης (VI) χωρίς την απομόνωση της ελεύθερης βάσης της 5 -[(R)-2 -(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1Η)-κινολιν-2-όνης. Τύπος (Α), (V): R = προστατευτική ομάδα, (VI): R = Η.
CY20091100993T 2003-02-28 2009-09-24 Μεθοδος για την παρασκευη αλατων 5-[(r)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1h)-κινολιν-2-ονης, τα οποια ειναι χρησιμα ως αγωνιστες αδρενεργικων υποδοχεων CY1109442T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45094503P 2003-02-28 2003-02-28
EP04715306A EP1599450B1 (en) 2003-02-28 2004-02-27 Process for preparing 5-[(r)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-(1h)-quinolin-2-one salts, useful as adrenoceptor agonists

Publications (1)

Publication Number Publication Date
CY1109442T1 true CY1109442T1 (el) 2014-08-13

Family

ID=32927689

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100993T CY1109442T1 (el) 2003-02-28 2009-09-24 Μεθοδος για την παρασκευη αλατων 5-[(r)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1h)-κινολιν-2-ονης, τα οποια ειναι χρησιμα ως αγωνιστες αδρενεργικων υποδοχεων

Country Status (30)

Country Link
US (1) US7534890B2 (el)
EP (1) EP1599450B1 (el)
JP (1) JP4802089B2 (el)
KR (1) KR101076929B1 (el)
CN (1) CN100363349C (el)
AR (1) AR043406A1 (el)
AT (1) ATE434609T1 (el)
AU (1) AU2004215647B2 (el)
BR (1) BRPI0407904B1 (el)
CA (1) CA2517033C (el)
CL (1) CL2004000381A1 (el)
CY (1) CY1109442T1 (el)
DE (1) DE602004021675D1 (el)
DK (1) DK1599450T3 (el)
EC (1) ECSP055977A (el)
ES (1) ES2326974T3 (el)
HK (1) HK1086255A1 (el)
IL (1) IL170138A (el)
MX (1) MXPA05009156A (el)
MY (1) MY142491A (el)
NO (1) NO331985B1 (el)
NZ (1) NZ541727A (el)
PE (1) PE20040956A1 (el)
PL (1) PL213932B1 (el)
PT (1) PT1599450E (el)
RU (1) RU2332405C2 (el)
SI (1) SI1599450T1 (el)
TW (1) TWI324150B (el)
WO (1) WO2004076422A1 (el)
ZA (1) ZA200506060B (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20050211A1 (es) * 2003-04-02 2005-04-27 Novartis Ag Procedimiento para preparar oxi-(1h)-quinolin-2-onas 5-(alfa-haloacetil)-8-sustituidas
EP1613315B1 (en) * 2003-04-04 2009-01-21 Novartis AG Quinoline-2-one-derivatives for the treatment of airways diseases
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds
US8198450B2 (en) * 2006-06-30 2012-06-12 Novartis Ag Quinolinone derivatives and their pharmaceutical compositions
CA2679059A1 (en) 2007-02-28 2008-09-04 Cipla Limited Process for preparing isomers of carmoterol
US8877930B2 (en) 2009-11-04 2014-11-04 Massachusetts Institute Of Technology Continuous flow synthesis of amino alcohols using microreactors
WO2011109276A1 (en) 2010-03-01 2011-09-09 Massachussets Institute Of Technology Epoxidation catalysts
WO2013132514A2 (en) * 2012-03-09 2013-09-12 Rao Davuluri Ramamohan A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2014008639A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 制备茚达特罗的方法
WO2014008640A1 (zh) * 2012-07-11 2014-01-16 上海威智医药科技有限公司 茚达特罗中间体及茚达特罗的合成方法
EP3848354B1 (en) 2012-09-21 2022-07-27 Crystal Pharma, S.A.U. Process for the preparation of indacaterol and intermediates thereof
WO2014044288A1 (en) * 2012-09-21 2014-03-27 Crystal Pharma Sa Methods for the preparation of indacaterol and pharmaceutically acceptable salts thereof
CZ306252B6 (cs) * 2013-03-15 2016-10-26 Zentiva, K.S. Způsob přípravy 5-[(R)-2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1H)-chinolin-2-onu (indacaterolu)
EP2978745B1 (en) 2013-03-27 2017-03-15 Laboratorios Lesvi, S.L. Process for the manufacture of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-quinolin-2-one
WO2015104718A2 (en) 2014-01-09 2015-07-16 Davuluri, Ramamohan Rao A novel process for preparation of indacaterol or its pharmaceutically acceptable salts
WO2016027283A2 (en) 2014-08-22 2016-02-25 Reddy G Pratap A process for preparing indacaterol and salts thereof
CN105693603B (zh) * 2014-11-24 2019-11-29 上海医药工业研究院 改良的马来酸茚达特罗制备工艺
CN107531636B (zh) * 2015-04-09 2022-11-25 正大天晴药业集团股份有限公司 茚达特罗或其盐的制备方法
CN107074833B (zh) * 2015-07-21 2021-05-25 四川海思科制药有限公司 具有β2受体激动及M3受体拮抗活性的苯并环衍生物及其在医药上的用途
WO2017055506A1 (en) 2015-09-29 2017-04-06 Laboratorios Lesvi, S.L. Mixed solvate of (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl] -8-hydroxy-1h-quinolin-2-one l-tartrate
CN107021921A (zh) * 2016-02-02 2017-08-08 常州爱诺新睿医药技术有限公司 一种茚达特罗中间体的盐及其制备方法
CN107868045A (zh) * 2016-09-28 2018-04-03 四川海思科制药有限公司 一种茚达特罗中间体的制备方法
CN108101841B (zh) * 2016-11-24 2021-04-06 江苏恒瑞医药股份有限公司 一种制备茚达特罗或其盐的方法
CN108264483A (zh) * 2016-12-31 2018-07-10 天津金耀集团有限公司 一种马来酸茚达特罗的制备方法
CN109516974B (zh) * 2017-09-19 2022-05-27 南京圣和药业股份有限公司 取代嘧啶类pi3k抑制剂的制备方法
EP3735406B1 (en) 2018-01-02 2022-05-11 Deva Holding Anonim Sirketi A process for preparation of 5-(2-(substituted-amino)-1-hydroxyethyl)-8-(substituted-oxy) quinolin-2(1h)-one
CN109721534B (zh) * 2018-09-25 2022-05-20 四川海思科制药有限公司 一种马来酸茚达特罗中间体及其制备方法和用途
CN109988111A (zh) * 2019-05-06 2019-07-09 淮北师范大学 一种马来酸茚达特罗的杂质及其合成方法
CN110128339B (zh) * 2019-05-31 2022-03-08 苏州芝宇生物科技有限公司 一种茚达特罗及其盐衍生物的合成方法和合成用中间体
CN113731406B (zh) * 2021-10-12 2023-07-28 南京工业大学 一种提高钯碳活性加氢脱除保护基的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
MXPA05009156A (es) 2005-10-20
SI1599450T1 (sl) 2009-12-31
AU2004215647B2 (en) 2006-12-21
HK1086255A1 (en) 2006-09-15
TWI324150B (en) 2010-05-01
TW200505864A (en) 2005-02-16
JP4802089B2 (ja) 2011-10-26
EP1599450A1 (en) 2005-11-30
CA2517033A1 (en) 2004-09-10
DK1599450T3 (da) 2009-10-05
KR20050105258A (ko) 2005-11-03
US20060252794A1 (en) 2006-11-09
ECSP055977A (es) 2006-01-16
ES2326974T3 (es) 2009-10-22
AR043406A1 (es) 2005-07-27
KR101076929B1 (ko) 2011-10-26
EP1599450B1 (en) 2009-06-24
RU2332405C2 (ru) 2008-08-27
IL170138A (en) 2011-09-27
JP2006519206A (ja) 2006-08-24
PT1599450E (pt) 2009-08-31
US7534890B2 (en) 2009-05-19
BRPI0407904B1 (pt) 2016-09-20
CL2004000381A1 (es) 2005-01-14
AU2004215647A1 (en) 2004-09-10
DE602004021675D1 (de) 2009-08-06
CN1753874A (zh) 2006-03-29
WO2004076422A1 (en) 2004-09-10
ZA200506060B (en) 2006-07-26
NO331985B1 (no) 2012-05-21
NO20054452L (no) 2005-11-28
BRPI0407904A (pt) 2006-02-14
PE20040956A1 (es) 2005-01-20
ATE434609T1 (de) 2009-07-15
NZ541727A (en) 2008-07-31
RU2005129547A (ru) 2007-04-10
PL378358A1 (pl) 2006-03-20
CN100363349C (zh) 2008-01-23
PL213932B1 (pl) 2013-05-31
NO20054452D0 (no) 2005-09-26
CA2517033C (en) 2011-11-15
MY142491A (en) 2010-11-30

Similar Documents

Publication Publication Date Title
CY1109442T1 (el) Μεθοδος για την παρασκευη αλατων 5-[(r)-2-(5,6-διαιθυλ-ινδαν-2-υλαμινο)-1-υδροξυ-αιθυλο]-8-υδροξυ-(1h)-κινολιν-2-ονης, τα οποια ειναι χρησιμα ως αγωνιστες αδρενεργικων υποδοχεων
IL165715A0 (en) 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives, pharmaceutical compositions containing the same and methods for the preparation thereof
CY1106980T1 (el) Παραγωγα ν-(αρυλοσουλφονυλο) βητα-αμινοξεων που φερουν μια ομαδα υποκαταστατου αμινοαιθυλιου, η διαδικασια παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
BR0308967A (pt) Derivados de quinolina e isoquinolina, um processo para a sua preparação e sua aplicação como inibidores de inflamação
EP1887007A3 (en) Imidazo- and Thiazolopyridine as JAK3 Kinase Inhibitors
WO2020016749A3 (en) Chemical process for preparing phenylpiperidinyl indole derivatives
BRPI0415288A (pt) composto, composição farmacêutica, método para tratar ou prevenir doenças, e, método para preparar o composto
IL174471A (en) A method for making quinolinone compounds and preparations containing such compounds
EA200401309A1 (ru) Тризамещённые гетероарилы и способы их получения и применения
ECSP034744A (es) Antagonistas de nmda/nr2b no arilo-heterociclico n-sustituidos
CY1106358T1 (el) Νεοι δικυκλικοι αναστολεις της ορμονοευαισθητης λιπασης
EP2308828A3 (en) CaSR antagonist
CY1109838T1 (el) Μεθοδος δια παρασκευη 3-ο-προστατευμενων μορφινονων και καρβοξυλικων αλατων διενολης 3-ο-προστατευμενης μορφινονης
CY1109637T1 (el) Νεα τρικυκλικα παραγωγα, η μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα περιεχουν
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS
CA2470809A1 (en) 6-amino-morphinan derivatives, method of manufacturing them and their application
EA200700550A1 (ru) Производные алкилидентетрагидронафталина, способ их получения и их применение в качестве противовоспалительных средств
EP1279665A3 (en) A process for the preparation of perindopril, its analogous compounds and salts thereof using 2,5-dioxo-oxazolidine intermediate compounds
EP1857459A3 (en) Pyrazolopyrimidine compound and a process for preparing the same
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
IL157540A (en) Pharmaceutical compositions comprising n-(aryl)-2-arylethenesulfonamides, some such novel compounds and process for their preparation
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
WO2004033423A3 (en) Anticancer compounds
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
DE60225943D1 (de) Topoisomerase-giftmittel